Course Catalog
Browse our full catalog of continuing education courses and events
Browse Courses & Events
Live Tumor Board: From Trial to Practice–Integrating the Latest Evidence Into the Treatment of EGFR-Mutated NSCLC
Jonathan Riess, MD, MS; Fawzi Abu Rous, MD; Julia Rotow, MD
Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application
April K.S. Salama, MD; Omid Hamid, MD; James M. G. Larkin, MD, PhD; Sapna Patel, MD
Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
Narjust Florez, MD, FASCO; David P. Carbone, MD, PhD; Edward B. Garon, MD, MS
Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD
Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; Millie Das, MD
Decoding HER2 Alterations in GEA: Best Practices for Testing and Treatment
Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rondell P. Graham, MBBS; Tanios S. Bekaii-Saab, MD
Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?
Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD
First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations
Rahul Gosain, MD, MBA; Rohit Gosain, MD; Adam Brufsky, MD, PhD
Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence
Rahul Gosain, MD, MBA; Rohit Gosain, MD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS
Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia
Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C
Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role
Naval Daver, MD; Courtney DiNardo, MD; Eunice Wang, MD
Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum
Manish A. Shah, MD, FASCO; Syma Iqbal, MD; Haeseong Park, MD, MPH
Cases and Conversations: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma
Marwan Fakih, MD; Kristen Ciombor, MD, MSCI; Van Karlyle Morris, MD
Collaborating Across the Continuum®: A Team-Based Approach to Earlier Detection and Smarter Treatment in LN
Shivani Garg, MD, PhD; Samir V. Parikh, MD, FASN; Kimberly DeQuattro, MD, MM
Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable, Early-Stage NSCLC
Mara Antonoff, MD, FACS; Laura Alder, MD; Stephanie Worrell, MD, FACS
“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments
Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD
Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data
John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE
Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC
Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD
Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes
Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD
The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights
Damon Dierker, OD FAAO; Maria Pribis, OD
Medical Crossfire®: Advancements in Chronic Myeloid Leukemia: Treatment Strategies, Mechanisms, and Patient Management
Jorge E. Cortes, MD; Hagop Kantarjian, MD; Neil P. Shah, MD, PhD; Kendra Sweet, MD
SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer
Rachel N. Grisham, MD
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 68th ASH Annual Meeting
April 10-11, 2027
Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies
Naval Daver, MD; Daniel A. Pollyea, MD; Gail J. Roboz, MD; Amer Zeidan, MBBS, MHS
Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations
Daniel J. DeAngelo, MD, PhD; Shira Dinner, MD; Stephen P. Hunger, MD; Jae H. Park, MD
Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care
Elias Jabbour, MD; Hagop Kantarjian, MD; Aaron Logan, MD, PhD, MPhil; Rob Pieters, MD, PhD; Claire R...
Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria
Caroline Piatek, MD; Jamile M. Shammo, MD, FASCP, FACP
PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma
Ajai Chari, MD; Maria-Victoria Mateos, MD, PhD; Mohamad Mohty, MD, PhD
Cases and Conversations: Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice
Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD
From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS
Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD
Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease
Biree Andemariam, MD; Nirmish Shah, MD
Burst CME™: Optimal Management of Complications of Sickle Cell Disease
Matthew Heeney, MD; Deepika S, Darbari, MD
Burst CME™: Disease-Modifying vs. Curative Therapy – Which Way to Go in Sickle Cell Disease?
Matthew Heeney, MD; Biree Andemariam, MD
Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification
Erin D. Michos, MD, MHS; Nihar Desai, MD, MPH
Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care
Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD
Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis
Abigail Schwaede, MD; Alexis Lizarraga, MD, MS
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Michelle Petri, MD, MPH; Shivani Garg, MD, PhD
Empowering HIV Management: Evidence-Based Prevention and Treatment Strategies
Onyema Ogbuagu, MD, FACP, FIDSA
Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis
James F. Howard Jr, MD, FAAN; Tuan Vu, MD
Community Practice Connections™: Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer
Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD
The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data
Rahul Gosain, MD, MBA; Rohit Gosain, MD
Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida
Carl J. Danzig, MD, FASRS
















































